Helicobacter Pylori
52
10
10
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 52 trials
100.0%
+13.5% vs benchmark
44%
23 trials in Phase 3/4
15%
3 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (52)
Keverprazan Combined With Amoxicillin for the Treatment of Helicobacter Pylori
Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy
Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies
H. Pylori Eradication With Argon Plasma During Endoscopy
Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection
Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans
Distribution Characteristics of Helicobacter Pylori
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori
14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection
Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Helicobacter Pylori and Vonoprazan Dual Therapy
Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
A Study of Vonoprazan in Adults With Helicobacter Pylori
Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy